Trials / Completed
CompletedNCT02771340
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Who Are Planned to Undergo Enucleation or Brachytherapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Iconic Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, biological activity, pharmacokinetics and pharmacodynamic activity of single and repeated escalating intravitreal doses of ICON-1 in patients with primary uveal melanoma who are planned to undergo enucleation or brachytherapy of the affected eye.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ICON-1 | Intravitreal injection of ICON-1 |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2016-05-13
- Last updated
- 2020-10-01
- Results posted
- 2020-09-14
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02771340. Inclusion in this directory is not an endorsement.